Clinical Trials

Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

Sponsor: National Heart, Lung, and Blood Institute

Enrollment: Completed in January 2011

Eligibility: Patients with Marfan syndrome between age 6 months and 25 years with a dilated aorta who have not had previous aortic surgery

Aim: To compare the effects of atenolol to those of losartan on the rate of aortic growth and progression of aortic regurgitation in patients with Marfan syndrome

Website: http://www.pediatricheartnetwork.com/marfan.asp

Additional Information

Tejani Mendiz-Ramdeen
Tel: (212) 241-6012
E-mail: tejani.mendiz-ramdeen@mssm.edu


Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) is an observational study to identify common genetic causes of congenital heart disease and genetic modifiers.

Sponsor: National Heart, Lung, and Blood Institute

Enrollment: Slated to run through October 2015 (possibly longer, if funding extended).

Eligibility: Individuals of all ages with congenital heart disease (CHD).Information about the medical history of the person with CHD and family members will be collected, along with DNA from the study participant, the participant's parents, and family members of interest.

Aim: To study relationships between genetic factors and the characteristics and clinical outcomes in patients with congenital heart defects (CHD). The study does not provide treatment for the CHD.

Website: http://www.benchtobassinet.com/PCGCresearch.asp

Additional Information

Tejani Mendiz-Ramdeen
Tel: (212) 241-6012
E-mail: tejani.mendiz-ramdeen@mssm.edu